Welcome to our dedicated page for Longeveron news (Ticker: LGVNR), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron LLC is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. Their lead investigational product candidate, LMSC, is based on a specialized cell known as a mesenchymal stem cell derived from the bone marrow of healthy young adult donors. The company's allogeneic, 'off-the-shelf' product is under investigation for chronic conditions of the elderly and other life-threatening diseases with no approved therapeutics currently available, including aging frailty syndrome, Alzheimer's disease, hypoplastic left heart syndrome, and the metabolic syndrome.
Longeveron Inc. (NASDAQ: LGVN) will report its first quarter 2024 financial results and provide a business update on May 14, 2024. The company, a clinical stage biotechnology firm focusing on regenerative medicines, will host a conference call and webcast at 5:00 p.m. ET the same day.
FAQ
What is Longeveron LLC known for?
What is LMSC?
What kind of diseases does Longeveron focus on?
What is the unique selling point of Longeveron's products?
Who are the investors of Longeveron Inc.?
How can one get in touch with Longeveron LLC?
What are the latest developments at Longeveron Inc.?
Where can I find more information about Longeveron Inc.?
What are the current projects of Longeveron LLC?